Found: 5
Select item for more details and to access through your institution.
Management of the National Drug Administration Through the Use of Biosimilar Medicines. Expenditures, Numbers of Reimbursed Packages and Shares of Biosimilar Products in the Infliximab Market a Year Prior to and a Year after the Introduction of the National Drug Policy 2018-2022.
- Published in:
- Management Issues / Problemy Zarządzania, 2020, v. 18, n. 3, p. 121, doi. 10.7172/1644-9584.89.7
- By:
- Publication type:
- Article
Nursing Care Plan for a Newborn with the Defect of Congenital Gastroschisis in the Postoperative Period Using ICNP TM and the Dedicated Software.
- Published in:
- International Journal of Environmental Research & Public Health, 2022, v. 19, n. 6, p. 3498, doi. 10.3390/ijerph19063498
- By:
- Publication type:
- Article
The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences.
- Published in:
- International Journal of Environmental Research & Public Health, 2021, v. 18, n. 13, p. 6952, doi. 10.3390/ijerph18136952
- By:
- Publication type:
- Article
Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access.
- Published in:
- Comparative Economic Research, 2020, v. 23, n. 2, p. 103, doi. 10.18778/1508-2008.23.15
- By:
- Publication type:
- Article
POLITYKA LEKOWA JAKO ELEMENT POLITYKI SPOŁECZNEJ -- WYZWANIA I ROZWIĄZANIA SYSTEMOWE NA PRZYKŁADZIE ROZPOWSZECHNIANIA LEKÓW BIOPODOBNYCH, PRZEGLĄD EUROPEJSKIEJ LITERATURY.
- Published in:
- Polityka Spoleczna, 2023, v. 592, n. 8, p. 17, doi. 10.5604/01.3001.0053.9025
- By:
- Publication type:
- Article